{
  "id": 7257343,
  "title": "AstraZeneca’s Etcamah trial misses primary endpoint",
  "url": "https://urgent.news/2026/09/14/astrazenecas-etcamah-trial-misses-primary-endpoint",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-14T06:14:38.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/astrazenecas-etcamah-trial-misses-primary-endpoint-93CH-4898838"
  },
  "original_language": "en",
  "account": "AstraZeneca has revealed that its Phase III clinical trial, SERENA-4, evaluating the effectiveness of Etcamah (camizestrant) in combination with palbociclib for first-line treatment of estrogen receptor-positive, HER2-negative advanced breast cancer, has failed to meet its primary endpoint of progression-free survival. The global study, which included 1,371 adult patients with Stage IV de novo or recurrent breast cancer, did not demonstrate a statistically significant improvement in progression-free survival when compared to the combination of an aromatase inhibitor, anastrozole, with palbociclib. Despite the disappointment, AstraZeneca's Executive Vice President of Oncology Haematology R&D, Susan Galbraith, emphasized that the outcome highlights the importance of maximizing Etcamah's benefits for patients based on the results of the subsequent SERENA-6 trial.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective",
        "url": "https://urgent.news/2026/09/14/astrazeneca-serena-4-trial-of-etcamah-palbociclib-combination-fails",
        "published": "2026-09-14T06:34:03.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}